Gastric Cancer
D702AC00001: A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer. (ARTEMIDE-Gastric01)
- Details
ClinicalTrials.gov ID:
NCT06764875
Diagnosis Type:
NA
USOR Number:
- Address
,
P: